Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered by an On-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (Subqsa)
Blood（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要